Adaptive Biotechnologies Corp (ADPT)vsWaters Corporation (WAT)
ADPT
Adaptive Biotechnologies Corp
$16.90
-6.53%
HEALTHCARE · Cap: $2.82B
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 1176% more annual revenue ($3.77B vs $295.41M). WAT leads profitability with a 11.9% profit margin vs -16.8%. WAT earns a higher WallStSmart Score of 50/100 (C-).
ADPT
Avoid30
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$31.45
Current Price
$16.90
$14.55 discount
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.1% year-over-year
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 12.4x book value
0.0% earnings growth
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 35.1% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Return on Equity.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while WAT is a growth play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.15 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
ADPT generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 30/100) and 91.4% revenue growth. ADPT offers better value entry with a 50.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?